Imris (NASDAQ:IMRS) is an early-stage Canadian medical equipment manufacturer and, as of this writing (6/24/13), is valued at $120 million or $2.32 per share. As of Q1/13, Imris is debt free with over $30M in cash on the balance sheet and has a backlog of $115.5M. Valuation is strongly driven by equipment bookings as those determine next year's revenue. Against a backdrop of global macroeconomic uncertainty, which in the United States was compounded by uncertainty over reimbursement, customer confidence has decreased. Hospitals delayed or froze spending on large capital equipment, which caused the company's 2011 bookings to decline to a modest $29 million and the stock price to decline by over 60%. In 2012, this spending freeze...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|